CurrentKaiser PermanentePolicy N/A

Endovenous Procedures for Varicose Veins

Customize your policy alerts

Sign up for all Kaiser Permanente policy alerts

Know when Kaiser Permanente releases new policies or updates existing guidance.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Clinical coverage criteria for endovenous ablation, sclerotherapy, phlebectomy, and related procedures for symptomatic varicose veins used by Quality Resource Management staff to determine medical necessity for members in the Georgia region.

Policy Summary

PayerKaiser Permanente

PolicyEndovenous Procedures for Varicose Veins

Policy CodePolicy N/A

Change TypeReviewed/Revised (no material clinical changes)

Effective DateN/A

Last ReviewMar 14, 2025

Next Review DateMar 15, 2025

Key ActionObtain prior authorization with documented duplex/Doppler evidence of reflux (>=500 ms), required vein diameter measurements, and a 3-month trial of conservative management when indicated.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

500 msminimum documented reflux duration required

4.5 mmsaphenous vein diameter threshold

OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

CurrentKaiser PermanentePolicy N/A

Endovenous Procedures for Varicose Veins

Customize your policy alerts

Sign up for all Kaiser Permanente policy alerts

Know when Kaiser Permanente releases new policies or updates existing guidance.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Policy Summary

PayerKaiser Permanente

PolicyEndovenous Procedures for Varicose Veins

Policy CodePolicy N/A

Change TypeReviewed/Revised (no material clinical changes)

Effective DateN/A

Last ReviewMar 14, 2025

Next Review DateMar 15, 2025

Key ActionObtain prior authorization with documented duplex/Doppler evidence of reflux (>=500 ms), required vein diameter measurements, and a 3-month trial of conservative management when indicated.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

500 msminimum documented reflux duration required

4.5 mmsaphenous vein diameter threshold

perforator vein diameter (under ulcer)

3 monthsconservative management trial

Medical Necessity Criteria

Primary criteria for endovenous ablation of saphenous veins

Covered when ALL of the following are met:

Saphenous ablation basic criteria

Clinical consequences: One of: ulceration secondary to venous stasis; episode of hemorrhage from a ruptured varicose vein; recurrent superficial thrombophlebitis; or severe and persistent pain/swelling or skin changes interfering with activities and requiring chronic analgesic medication despite a 3-month trial of conservative management.3-month conservative trial required unless exception applies

Incompetent perforating veins under ulcer

Covered when ALL of the following are met:

Perforator vein ablation: Incompetent perforating vein located underneath an active or healed venous stasis ulcer with vein diameter >= 3.5 mm and outward flow duration >= 500 ms.diameter >=3.5 mm; outward flow >=500 ms

Adjunctive treatment of accessory saphenous veins

Covered when ALL of the following are met:

Accessory saphenous adjunctive ablation: Accessory saphenous veins may be treated adjunctively when patient meets main endovenous ablation criteria and is being treated or has been treated for incompetence at the saphenofemoral or saphenopopliteal junction.

Ambulatory phlebectomy

Covered when ALL of the following are met:

Phlebectomy adjunctive treatment: Ambulatory or stab phlebectomy is medically necessary as adjunctive treatment for symptomatic varicose tributaries, accessory, and perforator veins >= 2.5 mm in diameter for persons who meet the medical necessity criteria for varicose vein treatment and who are being treated or have previously been treated for saphenous/saphenopopliteal incompetence.

Ambulatory phlebectomy and the TriVex system are considered cosmetic for all indications that do not meet the medical necessity criteria listed for varicose vein treatment. Ambulatory or stab phlebectomy is medically necessary as adjunctive treatment only for symptomatic varicose tributaries, accessory, and perforator veins with diameter >= 2.5 mm when the patient otherwise meets the policy criteria for treatment of saphenous/saphenopopliteal incompetence or has been treated for those conditions.

Sclerotherapy for asymptomatic spider veins is considered a purely cosmetic procedure and should not be approved as a covered benefit. Expert opinion cited in the policy states that sclerotherapy for asymptomatic spider veins is not an appropriate covered service.

Diagnosis & Procedure Codes, Measurement Thresholds

CPT/HCPCS codes referencedmixed

No codes listed

Reflux duration

ThresholdDocumented reflux duration >= 500 milliseconds (ms) in the vein to be treated.

Measurement methodDoppler or duplex ultrasound scanning must document incompetence and reflux duration.

ApplicabilityApplies to saphenous and target veins considered for endovenous ablation per primary criteria.

Saphenous vein diameter

ThresholdVein diameter >= 4.5 mm at a location other than the saphenofemoral junction.

Measurement contextDiameter requirement applied to saphenous veins being considered for endovenous ablation (non‑junction site).

Documentation, Authorization & Contraindications

Prior Authorization

Prior authorization: document ultrasound-proven reflux, vein size, and conservative therapy

Prior authorization must document ultrasound-proven venous incompetence and meet the policy's numeric thresholds: duplex/Doppler evidence of incompetence with reflux duration of 500 milliseconds or greater in the target vein, and target saphenous vein diameter of 4.5 mm or greater (measured at a non‑junction site). Prior authorization must also include evidence of a failed 3-month trial of conservative management when applicable; an exception to the trial requirement applies for persistent or recurrent varicosities after prior endovenous ablation/ligation/stripping in the same leg.

Doppler/duplex showing reflux duration >= 500 ms in the vein to be treated.
Saphenous vein diameter >= 4.5 mm at a location other than the saphenofemoral junction.
Documentation of a 3-month trial of conservative management unless the patient has persistent/recurrent varicosities after prior ablation/stripping/ligation in the same leg.

Step Therapy

Require documented 3‑month conservative management trial before procedure

Clinical Background

Varicose veins are elongated, tortuous superficial leg veins caused by valvular incompetence leading to reflux and venous hypertension. Clinical manifestations include aching, swelling, skin changes, recurrent superficial thrombophlebitis, bleeding from ruptured varices, and venous stasis ulcers. Treatment aims to eliminate reflux and reduce symptoms and complications by combining conservative measures (compression therapy, analgesia), sclerotherapy, surgical high ligation/stripping, endovenous thermal ablation (radiofrequency or laser), and adjunctive procedures such as ambulatory phlebectomy when indicated.

Definitions

Endovenous ablation definition

DefinitionMinimally invasive thermal occlusion of incompetent veins using radiofrequency (e.g., VNUS) or endovenous laser (EVLT/ELAS) to treat refluxing saphenous or perforator veins.

PurposePerformed to occlude refluxing truncal or perforating veins documented by duplex/Doppler when threshold criteria (reflux duration and diameter) are met.

Common targetsGreater saphenous, accessory saphenous, or small saphenous veins and select incompetent perforators under ulcers.

Ambulatory phlebectomy definition

DefinitionRemoval of symptomatic varicose tributaries, accessory, and perforator veins (>= 2.5 mm) by ambulatory or stab phlebectomy as adjunctive therapy to address residual localized varicosities.

Indication

Policy Summary

PayerKaiser Permanente

PolicyEndovenous Procedures for Varicose Veins

Policy CodePolicy N/A

Change TypeReviewed/Revised (no material clinical changes)

Effective DateN/A

Last ReviewMar 14, 2025

Next Review DateMar 15, 2025

Key ActionObtain prior authorization with documented duplex/Doppler evidence of reflux (>=500 ms), required vein diameter measurements, and a 3-month trial of conservative management when indicated.

SourceLink

On This Page

DocumentationVein size must be recorded on Doppler/duplex ultrasound used to demonstrate incompetence and eligibility.

Incompetent perforating vein diameter

ThresholdIncompetent perforating vein diameter >= 3.5 mm when located underneath an active or healed venous stasis ulcer.

Flow requirementOutward flow duration (reflux) of 500 milliseconds or more is required in addition to diameter.

Anatomic contextApplies specifically to perforating veins beneath an active or healed venous stasis ulcer being considered for endovenous ablation.

Phlebectomy vein diameter

ThresholdPhlebectomy is considered medically necessary for symptomatic tributaries, accessory, and perforator veins >= 2.5 mm in diameter when adjunctive to required saphenous treatment criteria.

Use caseAmbulatory or stab phlebectomy is an adjunctive treatment for residual localized varicosities in patients who meet main varicose vein treatment criteria.

Coverage limitationAmbulatory phlebectomy and the TriVex system are considered cosmetic for indications not meeting the listed medical necessity criteria.

Obtain and record a documented 3-month trial of conservative management (for example, analgesics and gradient compression stockings) before approving procedural treatment unless the patient has persistent or recurrent varicosities after prior endovenous catheter ablation or stripping/division/ligation in the same leg.

Conservative measures include analgesics and gradient support compression stockings.
No 3-month trial is required for persons with persistent/recurrent varicosities after prior ablation/stripping in the same leg.

Documentation Required

Required clinical documentation to support medical necessity

Include duplex/Doppler ultrasound results and clinical findings in the prior authorization or medical record: specifically reflux duration (>= 500 ms) in the target vein, measured vein diameters (e.g., saphenous >= 4.5 mm; perforator >= 3.5 mm under an ulcer), and the clinical consequence or symptom persistence after conservative therapy.

Duplex/Doppler demonstrating reflux duration >= 500 ms in the target vein.
Vein diameter measurements: saphenous >= 4.5 mm (non‑junction site); perforator >= 3.5 mm when located under an active or healed venous stasis ulcer.
Clinical documentation of ulceration, hemorrhage, recurrent superficial thrombophlebitis, or severe persistent symptoms despite a 3‑month conservative trial.

Denial Risk

Denial risk if duplex/Doppler reflux or required vein size not documented

Failure to provide duplex/Doppler evidence of incompetence (reflux >= 500 ms) or to document required vein diameters (e.g., saphenous < 4.5 mm at a non‑junction site) may result in denial of medical necessity for endovenous ablation procedures.

Absence of documented reflux duration >= 500 ms in the target vein is a denial risk.
Documented saphenous vein diameter less than 4.5 mm (at a non‑junction site) may lead to denial.

Note

Screen and document contraindications prior to procedure

Confirm and document absence of listed contraindications before performing endovenous procedures: pregnancy, current superficial thrombophlebitis in the vein to be treated, pulmonary emboli or hypercoagulable states, and allergy to sclerosing agents.

Pregnancy is a contraindication.
Current superficial thrombophlebitis in the target vein is a contraindication.
Pulmonary emboli and hypercoagulable states are contraindications.
Allergy to sclerosing agents is a contraindication.

Used adjunctively for patients who meet medical necessity criteria for varicose vein treatment and are being treated or have been treated for saphenous/saphenopopliteal incompetence.

Coverage noteAmbulatory phlebectomy (and the TriVex system) is considered cosmetic for indications that do not meet the listed medical necessity criteria.